Foresite Capital Buys $3.5 M of Alumis Shares at Discount, Signaling Confidence in TYK2 Pipeline.
Foresite Capital’s $17 stock buys show strong confidence in Alumis, a clinical‑stage biotech with a promising TYK2 pipeline—learn what this means for short‑term gains and long‑term prospects.
4 minutes to read